3 assets in Mitochondrial DNA Depletion Syndrome, Myopathic Form

Therapeutic assets addressing Mitochondrial DNA Depletion Syndrome, Myopathic Form, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione Mitochondrial DNA Depletion Syndrome, Myopathic Form	Cristina Domínguez González	P2	CCC (53)
Doxecitine Mitochondrial DNA Depletion Syndrome, Myopathic Form	Cristina Domínguez González	P2	CCC (53)
mt1621 Mitochondrial DNA Depletion Syndrome, Myopathic Form	Zogenix MDS, Inc.	P3	NR ()